Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 3/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 5/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843141 | 0.94 | MC4R (0.43) | MC4RMC3RMC1RCTSCREN | |
| SCHEMBL6845514 | 0.94 | MC4R (0.43) | MC4RMC3RMC1RCTSCREN | |
| SCHEMBL29394608 | 0.83 | CTSC (0.42) | MC4RMC3RMC1RCTSCREN | |
| SCHEMBL21883049 | 0.83 | NOS2 (0.51) | MC4RMC3RMC1RDPP4CTSC | |
| SCHEMBL13974141 | 0.81 | CTSC (0.58) | DPP4CTSCRENGHSR | |
| SCHEMBL11455942 | 0.81 | CTSC (0.40) | MC4RMC3RMC1RCTSCHTR2C | |
| SCHEMBL26510556 | 0.77 | CTSC (0.63) | DPP4CTSCHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7271124 | 0.76 | CTSC (0.61) | DPP4CTSCHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL10520878 | 0.76 | CTSC (0.61) | DPP4CTSCHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL10520881 | 0.76 | CTSC (0.61) | DPP4CTSCHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265212-A1 | Drug Transport and Delivery System | LUZERN ACQUISITION CORP., C/O STRELA DEVELOPMENT (CH) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265212-A1 | Drug Transport and Delivery System | DNPEP, PEPD, TAP1 | MC4R 2492/4885MC3R 1571/4885MC1R 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.